Dr. Bobby Lazzara reports on a clinical trial of aducanumab, a human monoclonal antibody, in patients with prodromal or mild Alzheimer disease.
Aducanumab, a human monoclonal antibody, selectively targets aggregated amyloid-Î². In this Medical News Minute, developed exclusively for Neurology Times, Dr. Bobby Lazzara discusses a one-year study of monthly intravenous infusions of aducanumab that has shown a slowing of clinical decline measurements in Alzheimer disease. A phase III trial of the drug is ongoing.
Related Content:Dementia and Alzheimer Disease